Evaluating the Efficacy of Fecal Occult Blood Test and Tumor Marker Combined Screening for Colorectal Cancer

Objective: To analyze the screening effectiveness of combining the fecal occult blood test with tumor marker detection for colorectal cancer. Methods: A total of thirty patients with colorectal cancer and thirty patients with benign colon hyperplasia who received treatment from January 2020 to January 2023 were selected. These patients were assigned to the observation group and the control group, respectively. All patients in both groups underwent both fecal occult blood tests and tumor marker detection. The levels of tumor markers between the two groups were compared, the tumor marker levels in different stages were assessed within the observation group, and the positive detection rates for single detection and combined detection were compared. Results: The levels of various tumor markers in the observation group were significantly higher than those in the control group (P < 0.05). Furthermore, as the Duke stage increased within the observation group, the levels of various tumor markers also increased (P < 0.05). The positive detection rate of the combined test was notably higher than that of single detection (P < 0.05). Conclusion: Combining the fecal occult blood test with tumor marker detection in colorectal cancer screening can significantly improve the overall detection rate.